{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T19:13:26Z","timestamp":1783710806845,"version":"3.55.0"},"reference-count":28,"publisher":"Xia & He Publishing","issue":"X","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9,28]]},"DOI":"10.14218\/jcth.2019.00016","type":"journal-article","created":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T23:17:41Z","timestamp":1566343061000},"page":"1-9","source":"Crossref","is-referenced-by-count":6,"title":["A Potential Functional Cure in Chinese HBeAg-negative Chronic Hepatitis B Patients Treated with Peg-interferon Alpha-2a"],"prefix":"10.14218","volume":"7","author":[{"given":"Xinyue","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianguo","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoguang","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifang","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiliang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanwei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fusheng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoren","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jidong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5334","published-online":{"date-parts":[[2019,8,20]]},"reference":[{"key":"key20190820231731_b1","article-title":"Global hepatitis report, 2017","author":"World Health Organization"},{"key":"key20190820231731_b2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","volume":"3","author":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"key20190820231731_b3","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3201\/eid2305.161477","article-title":"Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China","volume":"23","author":"Cui","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"key20190820231731_b4","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S1473-3099(15)00218-2","article-title":"Seroepidemiology of hepatitis B virus infection in 2 million men aged 21-49 years in rural China: a population-based, cross-sectional study","volume":"16","author":"Liu","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"key20190820231731_b5","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/cid\/civ859","article-title":"Epidemiology of hepatitis B and hepatitis C infections and benefits of programs for hepatitis prevention in northeastern China: A cross-sectional study","volume":"62","author":"Zhang","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key20190820231731_b6","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2011.12.061","article-title":"Epidemiology of viral hepatitis and hepatocellular carcinoma","volume":"142","author":"El-Serag","year":"2012","journal-title":"Gastroenterology"},{"key":"key20190820231731_b7","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/hep.23464","article-title":"Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus","volume":"51","author":"Simonetti","year":"2010","journal-title":"Hepatology"},{"key":"key20190820231731_b8","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1055\/s-2006-939751","article-title":"Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment","volume":"26","author":"Hadziyannis","year":"2006","journal-title":"Semin Liver Dis"},{"key":"key20190820231731_b9","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B","volume":"351","author":"Marcellin","year":"2004","journal-title":"N Engl J Med"},{"key":"key20190820231731_b10","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1473-3099(07)70264-5","article-title":"Therapeutic strategies in the management of patients with chronic hepatitis B virus infection","volume":"8","author":"Papatheodoridis","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"key20190820231731_b11","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","year":"2017","journal-title":"J Hepatol"},{"key":"key20190820231731_b12","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/S0168-8278(10)60100-6","article-title":"Extended (2 years) treatment with peginterferon alpha-2a [40kD] improves sustained response rates in genotype D patients with HBeAg negative chronic hepatitis B","volume":"52","author":"Lampertico","year":"2010","journal-title":"J Hepatol"},{"key":"key20190820231731_b13","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1097\/MEG.0b013e3283557e23","article-title":"Long-term follow-up of hepatitis B e antigen-negative patients treated with peginterferon \u03b1-2a: progressive decrease in hepatitis B surface antigen in responders","volume":"24","author":"Rijckborst","year":"2012","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"key20190820231731_b14","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1053\/j.gastro.2009.03.006","article-title":"Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a","volume":"136","author":"Marcellin","year":"2009","journal-title":"Gastroenterology"},{"key":"key20190820231731_b15","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/hep.22760","article-title":"Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B","volume":"49","author":"Brunetto","year":"2009","journal-title":"Hepatology"},{"key":"key20190820231731_b16","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s12072-012-9343-x","article-title":"Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients","volume":"7","author":"Marcellin","year":"2013","journal-title":"Hepatol Int"},{"key":"key20190820231731_b17","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/jmv.24013","article-title":"Extended peginterferon alfa-2a (Pegasys) therapy in Chinese patients with HBeAg-negative chronic hepatitis B","volume":"86","author":"Chen","year":"2014","journal-title":"J Med Virol"},{"key":"key20190820231731_b18","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jfma.2013.02.001","article-title":"Hepatitis B viral factors and treatment responses in chronic hepatitis B","volume":"112","author":"Lin","year":"2013","journal-title":"J Formos Med Assoc"},{"key":"key20190820231731_b19","doi-asserted-by":"crossref","first-page":"50","DOI":"10.7150\/ijms.2.50","article-title":"Epidemiology and prevention of hepatitis B virus infection","volume":"2","author":"Hou","year":"2005","journal-title":"Int J Med Sci"},{"key":"key20190820231731_b20","doi-asserted-by":"crossref","first-page":"297","DOI":"10.14218\/JCTH.2016.00019","article-title":"Guideline of prevention and treatment for chronic hepatitis B (2015 update)","volume":"5","author":"Hou","year":"2017","journal-title":"J Clin Transl Hepatol"},{"key":"key20190820231731_b21","doi-asserted-by":"crossref","first-page":"e3026","DOI":"10.1097\/MD.0000000000003026","article-title":"An observational, multicenter, cohort study evaluating the antiviral efficacy and safety in Korean patients with chronic hepatitis B receiving pegylated interferon-alpha 2a (pegasys): TRACES study","volume":"95","author":"Chon","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"key20190820231731_b22","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1136\/gutjnl-2011-301430","article-title":"Randomised study comparing 48 and 96 weeks peginterferon \u03b1-2a therapy in genotype D HBeAg-negative chronic hepatitis B","volume":"62","author":"Lampertico","year":"2013","journal-title":"Gut"},{"issue":"Suppl 1","key":"key20190820231731_b23","first-page":"44","article-title":"Effectiveness of pegylated-interferon alpha-2a (40KD) therapy in HBeAg negative Chinese patients with chronic hepatitis B at 3 years posttreatment: sub-analysis of the prospective, global, observational S-collate study","volume":"11","author":"Wei","year":"2017","journal-title":"Hepatol Int"},{"key":"key20190820231731_b24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14218\/JCTH.2018.00022","article-title":"Consensus on pegylated interferon alpha in treatment of chronic hepatitis B","volume":"6","author":"Zhang","year":"2018","journal-title":"J Clin Transl Hepatol"},{"key":"key20190820231731_b25","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","article-title":"HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability","volume":"63","author":"Kim","year":"2014","journal-title":"Gut"},{"key":"key20190820231731_b26","doi-asserted-by":"crossref","first-page":"E89","DOI":"10.1111\/hepr.12533","article-title":"Hepatic flares promote rapid decline of serum hepatitis B surface antigen (HBsAg) in patients with HBsAg seroclearance: A long-term follow-up study","volume":"46","author":"Nagaoka","year":"2016","journal-title":"Hepatol Res"},{"key":"key20190820231731_b27","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12985-015-0453-7","article-title":"Long-term effects of peginterferon alfa-2a therapy in Japanese patients with chronic hepatitis B virus infection","volume":"12","author":"Masaki","year":"2015","journal-title":"Virol J"},{"key":"key20190820231731_b28","author":"PEGASYS\u00ae (pegylated-interferon alpha-2a) injection, for subcutaneous use"}],"container-title":["Journal of Clinical and Translational Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.xiahepublishing.com\/2310-8819\/ArticleFullText.aspx?sid=2&id=10.14218%2fJCTH.2019.00016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T18:17:36Z","timestamp":1783707456000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.xiahepublishing.com\/2310-8819\/ArticleFullText.aspx?sid=2&id=10.14218%2fJCTH.2019.00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,20]]},"references-count":28,"journal-issue":{"issue":"X","published-online":{"date-parts":[[2019,8,20]]},"published-print":{"date-parts":[[2019,9,28]]}},"alternative-id":["10.14218\/JCTH.2019.00016"],"URL":"https:\/\/doi.org\/10.14218\/jcth.2019.00016","relation":{},"ISSN":["2225-0719","2310-8819"],"issn-type":[{"value":"2225-0719","type":"print"},{"value":"2310-8819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,20]]}}}